Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
Trial ID or NCT#
NCT00892931
Status
NOT RECRUITING
Purpose
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
Official Title
Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Have histologically proven malignant Glioblastoma Multiforme in first or second relapse - Have failed prior Fractionated External Beam Cranial Irradiation or IMRT - Be at least 18 years old and with a life expectancy ≥ 8 weeks or ≥ 4 weeks if failed prior Avastin therapy - Have a Karnofsky performance status of ≥ 60 - Have adequate bone marrow function, liver function, and renal function before starting therapy
Exclusion Criteria:
- - Have had more than two relapses - Have had radiosurgery - Have a cardiac ejection fraction < 50% by MUGA or ECHO - Have Troponin-I elevated above the normal range - Have an increasing steroid requirement - Have MRI evidence at baseline of enlarging or clinically significant intratumor hemorrhage - Have active stroke and/or transient ischemic attack not optimally managed - Have active cardiovascular disease (e.g. sub-optimally managed angina, impending myocardial infarction, or uncontrolled hypertension) - Be pregnant or breast feeding - Have had prior hypersensitivity reaction to Cremophor EL - Be HIV positive
Investigator(s)
Lawrence Recht, MD
Neuro-oncologist
Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
650-498-7061
View on ClinicalTrials.gov
